Sponsored by Image Analysis Group. Why the imaging platform decision is the single most consequential infrastructure choice a sponsor...

CONSONANCE's digitally enhanced MS endpoint cut required sample size 24.9%. Here's what that number costs in protocol amendments, IRB...

A Nature Biotechnology phase 2a trial ran six proteomic aging clocks simultaneously, here's what that means for biomarker strategy...

Advarra releases IRB reportable events checklist to help research teams distinguish critical safety signals from minor deviations requiring prompt...

Nektar will release 24-week off-treatment data for rezpegaldesleukin in alopecia areata, testing durability after dosing ends in the Phase...

JST-018 orthopoxvirus antibody enters phase 1 trial under $123.9M defense contract with Just-Evotec Biologics for warfighter protection.

BridgeBio shifts BBO-8520 focus to KRAS combinations in second-line NSCLC, building on a 63% response rate from monotherapy.

Novartis triggers $50M milestone payment as MRT-6160 enters Phase 2 for Sjögren's disease, advancing VAV1 degrader development.

Mosliciguat advances to Phase 3 PHrontier Trial after PHocus Study shows 20% pulmonary vascular resistance reduction in PH-ILD patients.

Six AI models picked the same "random" number. Clinical ops leaders are finally asking what that reveals about every...